Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Intra-Cellular Therapies Inc Market Cap
Based on ratings from 8 stock analysts, the Intra-Cellular Therapies Inc stock price is expected to increase by 10.92% in 12 months. This is calculated by using the average 12-month stock price forecast for Intra-Cellular Therapies Inc. The lowest target is $75.00 and the highest is $95.00. Please note analyst price targets are not guaranteed and could be missed completely.
ITCI is a stock in Health Care which has been forecasted to be worth $81.75 as an average. On the higher end, the forecast price is $95.00 USD by andrew tsai from Jefferies and on the lower end ITCI is forecasted to be $75.00 by joseph thome from TD Cowen.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| corinne jenkins Goldman Sachs | Hold | None | reiterated | Feb 8, 2024 |
| jessica fye J.P. Morgan | Buy | $75.0 | maintained | Feb 8, 2024 |
| corinne johnson Goldman Sachs | Hold | None | reiterated | Feb 8, 2024 |
| graig suvannavejh Mizuho Securities | Buy | $76.0 | reiterated | Feb 7, 2024 |
| brian abrahams RBC Capital | Buy | $86.0 | rated | Jan 31, 2024 |
| marc goodman Leerink Partners | Buy | $82.0 | maintained | Jan 21, 2024 |
| andrew tsai Jefferies | Buy | $95.0 | maintained | Jan 10, 2024 |
| jason gerberry Bank of America Securities | Buy | $82.0 | maintained | Jan 2, 2024 |
| joel beatty Robert W. Baird | Buy | $83.0 | initiatedcoverage | Jan 2, 2024 |
| joseph thome TD Cowen | Buy | $75.0 | initiatedcoverage | Dec 11, 2023 |
| ami fadia Needham | Buy | $72.0 | maintained | Nov 3, 2023 |
| charles duncan Cantor Fitzgerald | Buy | $101.0 | maintained | Nov 3, 2023 |
| sumant kulkarni Canaccord Genuity | Buy | $101.0 | maintained | Nov 2, 2023 |
| ashwani verma UBS | Buy | $80.0 | maintained | Jun 30, 2023 |
| jeffrey hung Morgan Stanley | Buy | $80.0 | initiatedcoverage | Apr 20, 2023 |
| robert hazlett BTIG | Buy | $57.0 | maintained | Mar 28, 2023 |
| david amsellem Piper Sandler | Hold | $59.0 | initiatedcoverage | Apr 22, 2022 |
| matthew kaplan Ladenburg Thalmann & Co. | Buy | $54.0 | maintained | Sep 10, 2020 |
| jason butler JMP Securities | Buy | $54.0 | maintained | Sep 9, 2020 |
| ritu baral Cowen & Co. | Hold | None | rated | Jul 12, 2019 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
When did it IPO
0
Staff Count
561
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Dr. Sharon Mates Ph.D.
Market Cap
$7.28B
In 2023, ITCI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ITCI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
LYFT-USD
$17.91
RGLD-USD
$108.65
$41.06
MASI-USD
$134.69
ALTR-USD
$89.86
HAS-USD
$50.19
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
